FDA Grants RMAT Status to Allogeneic CAR-T Therapies Cema-Cel and Lasme-Cel
Jul 30, 2026
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.